Sign inJoin waitlistJoin the waitlist

Andrew Kraft

Professor Emeritus · University of Arizona College of Medicine-Tucson

Credentials: · · ·

History

Hematology and Medical Oncology
1978–1981
Internal Medicine
Mount Sinai Hospital
1975–1978
Perelman School of Medicine at the University of Pennsylvania
1971–1975

Research

Phorbol esters increase the amount of Ca2+, phospholipid-dependent protein kinase associated with plasma membrane
Nature · 1983 · First of 2 authors · 1,368 citations
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
Journal of Clinical Oncology · 2009 · 450 citations
Decrease in cytosolic calcium/phospholipid-dependent protein kinase activity following phorbol ester treatment of EL4 thymoma cells
Journal of Biological Chemistry · 1982 · First of 4 authors · 413 citations

Michael Lilly
21 papers
MZ
Marina Zemskova
9 papers · 2 as a resident
Roger Berkow
9 papers
JB
Jeremiah Bearss
5 papers · 1 as a resident
SS
Scott Schuetze
4 papers
SF
Stuart Frank
4 papers
WM
W May
4 papers
Alberto Montero
3 papers
AM
Ali McBride
3 papers
CA
Cristina Antonescu
3 papers
Gary Schwartz
3 papers
RM
Robert Maki
3 papers

Grants

Regulation of RNA Decapping and Degradation: A Novel Approach to Prostate Cancer Therapy
National Cancer Institute · R43
Contact PI · $397.2K · Vortex Biotechnology Corporation
2023–2025
2/2 Partnership for Native American Cancer Prevention
National Cancer Institute · U54
PI · $1.7M · University of Arizona
2009–2024
University of Arizona Cancer Center - Cancer Center Support Grant
National Cancer Institute · P30
Contact PI · $18.2M · University of Arizona
1997–2021
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
National Cancer Institute · R01
Contact PI · $1.6M · University of Arizona
2013–2019

Clinical trials

Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Principal investigator · Completed · Phase 2
Medical University of South Carolina
2006–2013
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
Principal investigator · Terminated · Phase 2
Medical University of South Carolina
2004–2011
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
Principal investigator · Terminated · Phase 1
Medical University of South Carolina
2004–2007
Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery
Study chair · Terminated · Phase 2
Medical University of South Carolina
2005–2012